Although anti-estrogen therapy has significantly improved clinical outcomes of estrogen-dependent breast cancer patients, cytotoxic chemotherapy is still an important therapeutic option for patients with an aggressive phenotype of breast cancer, such as triple-negative breast cancer (TNBC), which lacks hormone both hormone receptors and human epidermal growth factor receptor 2 (HER2). This evidence concerns the gene ERBB2 and breast cancer.